Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | LPL | P06858 | 9/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16189763 | 1.00 | P2RX7 (0.85) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL2313496 | 1.00 | P2RX7 (0.85) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL2313492 | 1.00 | P2RX7 (0.85) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL17470588 | 1.00 | P2RX7 (0.85) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL19383987 | 1.00 | P2RX7 (0.85) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL422542 | 0.98 | P2RX7 (0.89) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL169762 | 0.92 | P2RX7 (1.00) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL30965858 | 0.86 | P2RX7 (0.80) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL14782402 | 0.83 | P2RX7 (0.65) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL19595278 | 0.83 | P2RX7 (0.65) | P2RX7MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034696-B2 | Compounds for inhibiting LRRK2 kinase activity | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-06-15 | — | — | US | disclosed |
| US-20210078951-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2021-03-18 | — | — | US | disclosed |
| US-10632103-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20170291905-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-12 | — | — | US | disclosed |
| US-20170267642-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9598374-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160024016-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-28 | — | — | US | disclosed |
| US-9120757-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20140315904-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034696-B2 | Compounds for inhibiting LRRK2 kinase activity | LRRK2, BRSK2, MAPKAPK2 | P2RX7 3517/4885MAPK1 92/4885LPL 1021/4885 |
| US-20210078951-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | P2RX7 4779/4885MAPK1 2329/4885LPL 1965/4885 |
| US-20170267642-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | P2RX7 4779/4885MAPK1 2329/4885LPL 1965/4885 |
| US-10632103-B2 | Arginine methyltransferase inhibitors and uses thereof | PRMT1, PRMT3, PRMT5 | P2RX7 4779/4885MAPK1 2329/4885LPL 1965/4885 |
| US-20140315904-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | P2RX7 4779/4885MAPK1 2329/4885LPL 1965/4885 |
| US-20160024016-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | P2RX7 4779/4885MAPK1 2329/4885LPL 1965/4885 |
| US-20170291905-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT6 | P2RX7 4834/4885MAPK1 2739/4885LPL 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.